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Abstract
Background: Atrial fibrillation (AF), a common arrhythmia contributing substantially to cardiac morbidity, is
associated with oxidative stress and, being an antioxidant, vitamin C might influence it.
Methods: We searched the Cochrane CENTRAL Register, MEDLINE, and Scopus databases for randomised trials on
vitamin C that measured AF as an outcome in high risk patients. The two authors independently assessed the trials
for inclusion, assessed the risk of bias, and extracted data. We pooled selected trials using the Mantel-Haenszel
method for the risk ratio (RR) and the inverse variance weighting for the effects on continuous outcomes.
Results: We identified 15 trials about preventing AF in high-risk patients, with 2050 subjects. Fourteen trials examined
post-operative AF (POAF) in cardiac surgery patients and one examined the recurrence of AF in cardioversion patients.
Five trials were carried out in the USA, five in Iran, three in Greece, one in Slovenia and one in Russia.
There was significant heterogeneity in the effect of vitamin C in preventing AF. In 5 trials carried out in the USA,
vitamin C did not prevent POAF with RR = 1.04 (95% CI: 0.86–1.27). In nine POAF trials conducted outside of the USA,
vitamin C decreased its incidence with RR = 0.56 (95% CI: 0.47–0.67). In the single cardioversion trial carried
out in Greece, vitamin C decreased the risk of AF recurrence by RR = 0.13 (95% CI: 0.02–0.92).
In the non-US cardiac surgery trials, vitamin C decreased the length of hospital stay by 12.6% (95% CI 8.4–16.8%) and
intensive care unit (ICU) stay by 8.0% (95% CI 3.0–13.0%). The US trials found no effect on hospital stay and
ICU stay. No adverse effects from vitamin C were reported in the 15 trials.
Conclusions: Our meta-analysis indicates that vitamin C may prevent post-operative atrial fibrillation in some countries
outside of the USA, and it may also shorten the duration of hospital stay and ICU stay of cardiac surgery patients.
Vitamin C is an essential nutrient that is safe and inexpensive. Further research is needed to determine the optimal
dosage protocol and to identify the patient groups that benefit the most.
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Background
Atrial fibrillation (AF) is a common cardiac rhythm dis-
turbance which can lead to severe consequences such as
stroke [1]. AF can be triggered by various stressful con-
ditions; for example, about 30% of patients undergoing
cardiac operations, such as coronary artery bypass graft-
ing (CABG), suffer from post-operative AF (POAF) [2].
AF is associated with oxidative stress and it seems that
the cause-effect relation may work in both directions. In
animal studies, tachycardia increased the levels of
oxidative stress markers [3, 4], while oxidative stress
increased the susceptibility of isolated hearts to tachy-
cardia [5]. Since several ion channels which are
expressed in the atria are sensitive to the redox state,
oxidative stress and antioxidants might influence the
electrophysiology of the atria [6].
Vitamin C is a water soluble antioxidant which may
protect against oxidative stress. In some studies, cardiac
surgery decreased vitamin C levels consistent with in-
creased oxidative stress [7–9]. There is also evidence
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that vitamin C may have a treatment effect on some
cardiovascular disorders. In patients undergoing cardiac
operations, vitamin C increased cardiac perfusion after
surgery [10], and decreased the level of creatine kinase
MB [11, 12]. A meta-analysis of patients with athero-
sclerosis or heart failure found that vitamin C improved
endothelial function [13], and another found that vita-
min C reduced blood pressure [14]. In addition, a recent
meta-analysis found that vitamin C decreased the risk of
contrast-induced acute kidney injury in patients under-
going coronary angiography [15].
In 2001, Carnes et al. reported that vitamin C adminis-
tration seemed to prevent POAF, but they used historical
controls instead of concurrent randomized controls [3].
Nevertheless, that study led to a series of randomized
trials on vitamin C against POAF.
AF is a common cardiac arrhythmia and vitamin C is
a safe and inexpensive essential nutrient. Approximately
0.01 g/day of vitamin C prevents scurvy but the safe
dose range extends to grams per day [16, 17]. The possi-
bility that vitamin C might have preventive effects
against AF, even in restricted population groups, is
worth examination. The goal of this systematic review
was to analyse the preventive effect of vitamin C against
AF in patients with a high risk of AF.
Methods
Selection criteria for trials and the searches
We selected randomized controlled vitamin C trials
which measured the occurrence of AF in patients at a
high risk of AF. We considered high risk patients as
those undergoing cardiac surgery and those going to car-
dioversion for whom there is a high risk of recurrence of
AF. The use of placebo in the control group was not re-
quired. We did not set limits on the dose or duration of
vitamin C administration. We searched the Cochrane
Register (CENTRAL; Cochrane Library), MEDLINE
(Ovid) and Scopus (Ovid). We searched all databases
from their inception to December 4, 2016, and we im-
posed no restriction on the language of publication. The
search strategies are detailed in Fig. 1. We also searched
ClinicalTrials.gov and the WHO International Clinical
Trials Registry Platform (ICTRP) under “vitamin C” and
“fibrillation”. We checked reference lists of the trials in-
cluded and relevant reviews, and contacted the authors
of published trials to ask if they knew of ongoing or un-
published trials. We included trials reported as full-text
or abstract, and also unpublished trials. We identified 15
trials in all [18–32] (Fig. 1; Table 1; Additional file 1).
Outcomes
Our primary outcome was the occurrence of AF. As
secondary outcomes, we analysed the length of hospital
stay and the length of intensive care unit (ICU) stay.
Selection of studies and data extraction
The two authors independently screened the titles and
abstracts, and identified trials for inclusion. One author
(HH) extracted study characteristics and outcomes from
the trials and entered the data to the Review Manager 5
Fig. 1 Flow diagram of the searches. The search terms and the number of identified records are shown in this figure
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(RevMan) program [33]. Both authors checked the data
entered in the RevMan program against the original trial
reports. We contacted all authors to ask for more details
(see Additional file 1).
Quality assessment of the trials
Both authors assessed the quality of included trials using
the Cochrane Collaboration’s tool for assessing the risk
of bias, our assessments being shown in the Additional
file 1. We assessed the trials for the following criteria:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, selective
reporting, and other bias. We gave each item a designa-
tion of high, low, or unclear risk of bias.
Statistical methods
We analysed dichotomous data on the incidence of AF
as risk ratios (RR). Our main analysis of continuous data
was as percentage effects, since that adjusts for baseline
variations between trials. For the length of hospital stay,
we also calculated the effect of vitamin C on the number
of days the patient stayed at the hospital.
Some studies used the Mann–Whitney test in the cal-
culation of the P-values since, for skewed data such as
the length of hospital stay, it is preferable to the t-test.
In some trials, the Mann–Whitney P-values calculated
by the original authors were incompatible with the re-
ported SD values. Therefore, in 3 studies we adjusted
the SD values for hospital stay [21, 23, 31], and in 2
studies we adjusted the SD values for ICU stay [21, 23],
to make them consistent with the Mann–Whitney P-
values; see the Additional file 1.
In the Korantzopoulos trial [32], 1 cell in the 2 × 2
table had only 1 case of AF recurrence. We therefore
calculated the P-value by the mid-P modification of the
Fisher exact test [34].
We pooled the selected trials with the RevMan pro-
gram, using the Mantel-Haenszel option for RRs and the
inverse variance option for continuous outcomes, with
the fixed effect option for both. We used the Chi2 test
and the I2 statistic to assess statistical heterogeneity
among the trials in each meta-analysis [35]. A value of I2
greater than about 70% indicates a high level of hetero-
geneity. We used 2-tailed P values in this review.
Results
Description of the trials
We identified 15 trials which examined the effect of vita-
min C on preventing AF in patients at a high risk of AF
[18–32]. See the flow diagram of the searches in Fig. 1.
Fourteen trials examined patients undergoing cardiac
surgery, either CABG [18–27] or CABG and valvular
surgery [28–31]. The 15th trial examined the recurrence
of AF after a successful cardioversion [32] (Table 1).
Five trials were carried out in the USA [18, 27–30], 5
in Iran [19, 20, 25, 26, 31], 3 in Greece [21, 22, 32], 1 in
Slovenia [23], and 1 in Russia [24]. The total number of
participants was 2050. The mean age ranged from 56 to
73 years, and the proportion of males varied from 59 to
Table 1 Characteristics of included trials
Trial (ref.) Country Setting No. of Participants Mean age (yr) Proportion males
van Wagoner 2003 [27] USA CABG 346 63 NA
Donovan 2012 [30] USA CABG or valvular surgery 304 64 76%
Sadeghpour 2015 [31] Iran CABG or valvular surgery 290 56 66%
Bjordahl 2012 [18] USA CABG 185 63 67%
Papoulidis 2011 [21] Greece CABG 170 73 71%
Sarzaeem 2014 [26] Iran CABG 170 59 69%
Samadikhah 2014 [25] Iran CABG 120 61 68%
Antonic 2016 [23] Slovenia CABG 105 64 78%
Dehghani 2014 [19] Iran CABG 100 61 74%
Eslami 2007 [20] Iran CABG 100 60 67%
Korantzopoulos 2005 [32] Greece Cardioversion 44 68 59%
Rebrova 2012 [24] Russia CABG 40 59 100%
Healy 2010 [29] USA CABG or valvular surgery 30 NA NA
Colby 2011 [28] USA CABG or valvular surgery 24 65 79%
Polymeropoulos 2015 [22] Greece CABG 22 70 59%
The trials are listed by the number of patients. The two largest trials [27, 30], both carried out at the USA, have not been published because of their negative
findings. For the US trials, the weighted mean age was 63.4 years and for the non-US trials, it was 61.8 years. For the US trials, the overall proportion of males was
73%, and for the non-US trials, it was 70%
CABG Coronary artery bypass grafting, NA Not available
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100% (median 69%) in the trials that reported sex distri-
bution (Table 1).
Most POAF trials administered 2 g of vitamin C
within about 12 h before the operation and 1–2 g/day
for 5 days after the operation, and followed patients for
the occurrence of AF for the same period. In most trials,
vitamin C was administered as tablets, although 5 trials
administered it intravenously [21–23, 26, 31]. See the
description of dosages in the Additional file 1.
In the cardioversion trial [32], 2 g vitamin C was ad-
ministered before the cardioversion and thereafter 1 g/
day of vitamin C for 7 days. After a successful cardiover-
sion, participants were followed for 7 days for the recur-
rence of AF.
Because of the selection criteria, all the trials were ran-
domized. Korantzopoulos et al. [32] mentioned that the
cardioversion patients bought vitamin C tablets them-
selves and thus knew the treatment, but the physician
who was responsible for cardioversion and follow-up
was unaware of the treatment. A placebo was not used
in 6 POAF trials [19, 20, 23, 24, 29, 32], but in other tri-
als participants were administered a placebo. Four trials
[23, 24, 29, 32] did not report that the physicians in
charge of treatments and assessment of outcome were
blinded, but in other trials that was the case. None of
the trials had substantial or unbalanced drop-out rates.
See the Additional file 1 for the details of the methods.
Effect of vitamin C on atrial fibrillation
Figure 2 shows the effect of vitamin C on the occurrence
of AF in high risk patients. Over all the 15 trials, vitamin
C decreased the risk of AF by 27%. However, there is
Fig. 2 Effect of vitamin C on the occurrence of AF in high risk patients. The upper three subgroups are trials on POAF and the lowest subgroup
includes the cardioversion study. The horizontal lines indicate the 95% CI for the effect of vitamin C and the square in the middle of the
horizontal line indicates the point estimate of the effect in the particular trial. The diamond shapes indicate the pooled effects on the symptoms
and its 95% CI
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significant heterogeneity between the 15 trials with I2 =
61% (P = 0.001 in the heterogeneity test), which indicates
that no single estimate of effect, such as the 27% mean
effect, is consistent with the results of all the 15 trials,
and thus the causes of the heterogeneity should be
explored.
Because of the variations in the clinical context and
in the results, we divided all the trials into 4
subgroups. The 14 trials on POAF were divided into
trials carried out a) in the USA, b) in Greece,
Slovenia, and Russia, and c) in Iran, and the 15th
trial is included as d) the cardioversion trial in
Greece (Fig. 2). There is very strong evidence that the
estimates calculated for these 4 subgroups are hetero-
geneous with I2 = 88% (P = 10−5). The high level of
heterogeneity is caused by the US trials, which found
no effect of vitamin C. If the 5 US trials are removed,
the remaining 10 non-US trials are not heteroge-
neous, I2 = 38% (P = 0.10), and the pooled estimate in-
dicates a 45% decrease (95% CI 35 to 54%; P = 10−10)
in the occurrence of AF. If we further remove 4 non-US
trials that had some concerns about randomization or
blinding [23, 24, 31, 32], the effect estimate remains
essentially the same indicating a 48% (95% CI 34 to 60%)
decrease in the incidence of AF (see Additional file 2).
Thus, there is very strong evidence from the 10 non-US
trials that vitamin C decreases the risk of AF in high risk
patients.
The 5 POAF trials in Iran found a 51% decrease in the
incidence of AF and the 4 POAF trials in Greece,
Slovenia, and Russia found a 29% decrease. When these
9 trials were pooled to a group of non-US POAF trials,
vitamin C decreased the incidence of AF by 44% (33 to
53%) (Fig. 3).
In a direct comparison of the 5 US POAF trials against
the 5 Iran POAF trials, there is very strong evidence of
heterogeneity with I2 = 95% (P = 10−5) (Additional file 2).
Thus, vitamin C seems to have significantly different ef-
fect in these two countries.
Korantzopoulos et al. studied the recurrence of AF
within 1 week after a successful cardioversion, finding
that vitamin C decreased the rate of AF recurrence by
87% (P = 0.012).
All the POAF trials administered 1–2 g/day of vitamin
C. Most trials gave it as tablets, whereas 5 gave it intra-
venously. These 2 methods of administration lead to dif-
ferent vitamin C levels in the body and we compared the
2 methods among the non-US POAF trials in Fig. 3.
Oral administration decreased the occurrence of POAF
by 73% and intravenous administration by 36%. There is
strong evidence of heterogeneity between the 2 adminis-
tration methods with I2 = 87% (P = 0.005).
Effect of vitamin C on hospital stay
The effect of vitamin C on the hospital stay in 11 POAF
trials is shown in Fig. 4. On average, vitamin C
Fig. 3 Effect of vitamin C on the occurrence of POAF in non-US trials by vitamin C administration method. The trials in the upper subgroup ad-
ministered vitamin C intravenously and the trials in the lower subgroup administered it orally. The horizontal lines indicate the 95% CI for the vita-
min C effect and the square in the middle of the horizontal line indicates the point estimate of the effect in the particular trial. The diamond
shapes indicate the pooled effects on the symptoms and its 95% CI
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shortened the hospital stay by 10.1%. Because of the het-
erogeneity found in the effects of vitamin C against
POAF, we divided the trials into the US and the non-US
trials also in this analysis. The US trials found no effect
on hospital stay whereas in the non-US cardiac surgery
trials, vitamin C decreased the length of hospital stay by
12.6% (95% CI 8.4 to 16.8%; P = 10−8). Only 1 of the
non-US trials had some concerns about blinding [23],
and its exclusion had only a small effect on the pooled
effect estimate indicating a 13.3% (9.0 to 17.6%) decrease
in the length of hospital stay (Additional file 2).
The non-US trials were further divided into oral and
intravenous trials. There is strong evidence of hetero-
geneity between the 3 subgroups with I2 = 78% (P =
0.009) (Fig. 4). In the non-US trials, intravenous admin-
istration shortened the length of hospital stay by 16%
and oral administration by 7% and there was evidence of
heterogeneity between the oral and intravenous non-US
trials with I2 = 76% (P = 0.039).
The relative effect, i.e., the effect in percentages, ad-
justs for baseline variations in the patient groups and is
therefore an informative effect measure when pooling
trial results in Fig. 4. Nevertheless, since the effect on
hospital stay as actual days has more direct practical im-
pact, we also calculated the effect of vitamin C on the
days in hospital in Fig. 5. In the non-US trials,
intravenous vitamin C shortened hospital stay on aver-
age by 1.47 days and oral vitamin C by 0.43 days.
Since oral and intravenous vitamin C differed in their
effects on the occurrence of POAF and on the duration
of hospital stay, we plotted the estimates of effect in
Fig. 6. In the non-US trials, oral vitamin led to a greater
effect on POAF occurrence but to a lesser effect on hos-
pital stay compared with intravenous vitamin C. The US
trials found no benefit on either outcome.
Effect of vitamin C on ICU stay
The effect of vitamin C on the length of ICU stay in the
POAF trials is shown in Fig. 7. Vitamin C shortened
ICU stay by 8% (P = 0.002) in the 7 non-US trials and
there is no evidence of heterogeneity between the non-
US trials (P = 0.1). Three US trials found no effect.
Discussion
Our systematic review was formulated as an examination
of the effects of vitamin C on the occurrence of AF in
people at a high risk for AF. Since patients undergoing
cardiac surgery and cardioversion may suffer from acute
oxidative stress, vitamin C administration might have an
influence in such special conditions. We found 15 ran-
domized trials on vitamin C for preventing AF in high
risk patients. On average, vitamin C decreased the
Fig. 4 Effect of vitamin C on the length of hospital stay in percentages. The subgroup on the top includes the US trials, all of which administered
vitamin C orally. The non-US trials are divided into groups by oral and intravenous vitamin C administration. The durations of hospital stay were
transformed to the relative scale; thus the duration in the corresponding placebo group was given a value of 100%. Thereby the difference
between the vitamin C and control groups gives the effect of vitamin C directly as a percentage. The horizontal lines indicate the 95% CI for the
vitamin C effect and the square in the middle of the horizontal line indicates the point estimate of the effect in the particular trial. The diamond
shapes indicate the pooled effects on the symptoms and their 95% CI
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occurrence of AF by 27%, but there was significant het-
erogeneity in the results. We also found a 10% decrease
in hospital stay in cardiac surgery patients. Heterogen-
eity indicates that a single average estimate of effect can-
not be valid for all of the 15 trials and justified
exploration to identify the causes of this heterogeneity.
Five of the trials included in Fig. 2 were carried out in
Iran and the pooled estimate indicates a 51% reduction
in POAF incidence with vitamin C administration. In
contrast, 5 trials in the USA found that vitamin C
produced no benefit. These 2 sets of trials are signifi-
cantly incompatible. We do not consider that methodo-
logical differences between the US and Iran trials are the
most likely explanations for the divergence between
these 2 sets of trials. Previous research has pointed out
that treatment effects can differ between less and more
developed countries. Panagiotou et al. [36] found several
cases in which trials in less developed countries showed
more favourable treatment effects than trials in more de-
veloped countries. Although methodological variations
may explain some of the differences, it is also likely that
there are genuine differences between many treatment
effects between substantially different cultures. Wealth is
strongly correlated with life-style factors including nutri-
tion, and with differences in hospital treatments. Such
differences might explain the divergence between the re-
sults in the 5 US and the 5 Iran POAF trials.
Among the non-US trials, oral vitamin C had a greater
effect on POAF occurrence than intravenous vitamin C
(Fig. 3). There is a substantial difference in the pharma-
cokinetics between oral and intravenous vitamin C, so
that the same intravenous dose leads to much higher
vitamin levels in plasma than the oral dose [16, 37]. Fur-
thermore, intravenous vitamin C may be more reliable
for postoperative patients since delayed gastric emptying
is a frequent concern. Therefore the greater effect of oral
vitamin C on POAF occurrence was against our expect-
ation. On the other hand, the greater effect of intraven-
ous vitamin C on the hospital stay is consistent with
greater effects of higher plasma levels.
POAF has previously been correlated with a longer
stay in hospital, but it is not known whether the longer
hospital stay is caused by the episode of POAF or
Fig. 5 Effect of vitamin C on the length of hospital stay in days. The non-US trials are divided into groups by oral and intravenous vitamin C
administration. The US trials are not shown since they found no effect of vitamin C on hospital stay (Fig. 4). The horizontal lines indicate the
95% CI for the vitamin C effect and the square in the middle of the horizontal line indicates the point estimate of the effect in the particular trial.
The diamond shapes indicate the pooled effects on the symptoms and their 95% CI
Fig. 6 Effect of oral and intravenous vitamin C on POAF and on
hospital stay. The open square indicates the pooled effect of oral
vitamin C in the non-US trials and the filled in square indicates the
pooled effect of intravenous vitamin C trials in the non-US trials. The
open circle indicates the pooled effect of oral vitamin C in the US
trials. The estimates are from Figs. 2, 3 and 4. The horizontal and
vertical lines indicate the 95% CI ranges for each effect. The Rebrova
(2012) [24] and Samadikhah (2014) [25] trials contribute to the esti-
mate of oral vitamin C effect on POAF occurrence in the non-US
trials, but they did not report the findings on hospital stay
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whether both of them are caused by other factors [38].
Among the non-US trials, oral vitamin C had a greater
effect on POAF, but a smaller effect on hospital stay
compared with intravenous vitamin C (Fig. 6). This
negative correlation between the effects on POAF and
on hospital stay conflicts with the notion that POAF is
the cause of a longer hospital stay. The divergence we
found in the effects of oral and intravenous vitamin C
administration indicates that the 2 methods of vitamin C
administration should be further studied by head-to-
head comparisons in 3-arm randomized trials instead of
just comparing independent trials that have various
other differences simultaneously.
As the methodological inclusion criterion, we required
that the trials be randomized. Six trials with cardiac sur-
gery patients did not use an explicit placebo [19, 20, 23,
24, 29, 32]. However, other medications serve as a func-
tional placebo to vitamin C in cardiac surgery trials. It
seems highly unlikely that such patients might notice
whether vitamin C is administered along with the other
medications, so that the lack of an explicit placebo
would substantially bias observations in the 5 trials.
Three POAF trials [23, 24, 29] did not report that physi-
cians in charge of treatments and outcome assessment
were blinded for the trial groups, but in other trials they
were blinded. In the Korantzopoulos et al. trial on the
recurrence of AF after cardioversion, patients bought
vitamin C tablets themselves and knew their treatment
[32]. However, a large meta-analysis showed that placebo
has minimal or no effects on binary outcomes [39], such
as the occurrence of AF.
In sensitivity analyses, we excluded trials that had
some concerns about possible bias in the comparison.
However, the estimates of vitamin C effects were not
changed. In addition, the heterogeneity between the
US and the non-US trials was not influenced by the
exclusion of trials that had some concerns about pos-
sible bias.
Two relatively large US trials on POAF were not
published because their results were negative [27,
30]. Nevertheless, we do not consider that publica-
tion bias is a likely explanation for our main find-
ings. The evidence of the benefit of vitamin C in the
non-US trials is very strong and there should be a
particularly large number of unpublished non-US
trials to explain the findings purely as a result of re-
searchers publishing just the positive findings. In
particular, publication bias is not a reasonable ex-
planation for the significant difference between oral
and intravenous administration.
In the first study on vitamin C for preventing
POAF, Carnes et al. described their protocol as fol-
lows: “patients scheduled for primary CABG surgery
were given 2 g ascorbic acid (extended release) the
night before surgery, followed by 500-mg doses twice
daily for the 5 days after surgery” [3]. All subsequent
POAF trials used dosage protocols that are only
minor modifications of the Carnes method. Although
the first question after the publication of a positive
result should be whether the result can be repeated,
subsequent trials should also investigate protocol
variations to determine the optimal protocol.
Fig. 7 Effect of vitamin C on the length of ICU stay. The US and non-US trials are separated in this figure. The durations of ICU stay were trans-
formed to the relative scale; thus the duration in the corresponding placebo group was given a value of 100%. Thereby the difference between
the vitamin C and control groups gives the effect of vitamin C directly as a percentage. The horizontal lines indicate the 95% CI for the vitamin
C effect and the square in the middle of the horizontal line indicates the point estimate of the effect in the particular trial. The diamond shapes
indicate the pooled effects on the symptoms and their 95% CI
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Vitamin C is water soluble, and its concentration in
plasma increases within 1–2 h of oral administration
and decreases thereafter [16, 37]. On the basis of such
pharmacokinetics, it seems unlikely that several days ad-
ministration before the cardiac operation might lead to
further benefits. In 2 POAF trials, vitamin C was admin-
istered intravenously 3 h before the operation [21] or
immediately before [31] and both produced a significant
benefit. Longer administration before the operation
might not be needed.
Another time-dependent question is about the length
of vitamin C administration after the operation. In the
POAF trials, vitamin C administration was continued for
5 days after the operation and the cardioversion trial
continued administration for 7 days. Assuming that the
greatest peak of oxidative stress occurs during and soon
after the operation or cardioversion, a shorter adminis-
tration period might be sufficient. In a trial with severe
burn patients, vitamin C was administered intravenously
for only 24 h after hospitalization but the dose was par-
ticularly high with 66 mg/kg/h (i.e., 110 g per 70 kg per
24 h) [40]. Compared with the control group, the level
of vitamin C remained much higher in the vitamin
groups for 3 days. In the vitamin C group, the length of
mechanical ventilation was 43% shorter (P = 0.03) and
there was a significant decrease in the requirement for
infusion fluids [40], indicating that such a 1-day admin-
istration at a particularly high dose level might also be
effective. Accordingly, the dose and the length of vita-
min C administration should also be investigated in fur-
ther trials.
Conclusions
Trials carried out in Iran and Greece indicate that
vitamin C may prevent AF after cardiac surgery or
cardioversion. However, trials with cardiac surgery pa-
tients carried out in the USA found no benefit. Thus,
trials in less wealthy countries should be carried out
to optimize the protocol for vitamin C administration
and to determine which patient groups get the most
benefit, for example, by examining vitamin C status
before the cardiac operation or cardioversion. Further
trials in wealthy countries may investigate the effect
of vitamin C against AF in patients who have a par-
ticularly low documented level of vitamin C, but
there seems to be no rationale to study unselected
cardiac surgery patients further.
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